Tomohiro Fujii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tomohiro Fujii has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Yutaka Matsuda
Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki, Kanagawa 210-8681, Japan
13 shared publications - Takuya Seki
Ajinomoto (Japan)
4 shared publications - Tomohiro Watanabe
Ajinomoto (Japan)
4 shared publications - Akira Nakayama
Ajinomoto (Japan)
3 shared publications - Kazutaka Shimbo
Ajinomoto (Japan)
3 shared publications - Kazutoshi Takahashi
Research Institute for Bioscience Products & Fine Chemicals, Ajinomoto Co., Inc., Kawasaki-shi, Japan
3 shared publications
Latest Publications
- 1 May 2026
- Published by Springer Nature
- Vol. 2997, 107-118
Enhanced Chemical Method for Bispecific Antibody Production: Leveraging Site-Specific Conjugation and Stable Crosslinker Technology
Bispecific antibodies (BisAbs) represent a major breakthrough in biotherapeutics by combining the functionalities of two different antibodies to unlock their potential for a wide range of applications. Conventional BisAb production has relied on labor-intensive and complex genetic engineering methods. This chapter introduces a cutting-edge protocol that circumvents the need for genetic modifications by using chemical conjugation strategies. We present a streamlined, fully chemical methodology for generating BisAbs that leverages the precision of the AJICAP second-generation technology for accurate site-specific conjugation. In addition, this chapter explores the application of haloketone chemistry as an improved and more effective replacement for traditional maleimide-based crosslinking techniques for the fusion of two antibody-related proteins. The analytical performance and results of the newly developed BisAb were thoroughly investigated, highlighting its high efficiency and effectiveness. This innovative approach represents a significant step forward in the production of BisAbs and offers a simpler, more accessible, and potentially scalable alternative to traditional genetic engineering techniques.
- 1 May 2026
- Published by Springer Nature
- Vol. 2997, 107-118
Enhanced Chemical Method for Bispecific Antibody Production: Leveraging Site-Specific Conjugation and Stable Crosslinker Technology
Bispecific antibodies (BisAbs) represent a major breakthrough in biotherapeutics by combining the functionalities of two different antibodies to unlock their potential for a wide range of applications. Conventional BisAb production has relied on labor-intensive and complex genetic engineering methods. This chapter introduces a cutting-edge protocol that circumvents the need for genetic modifications by using chemical conjugation strategies. We present a streamlined, fully chemical methodology for generating BisAbs that leverages the precision of the AJICAP second-generation technology for accurate site-specific conjugation. In addition, this chapter explores the application of haloketone chemistry as an improved and more effective replacement for traditional maleimide-based crosslinking techniques for the fusion of two antibody-related proteins. The analytical performance and results of the newly developed BisAb were thoroughly investigated, highlighting its high efficiency and effectiveness. This innovative approach represents a significant step forward in the production of BisAbs and offers a simpler, more accessible, and potentially scalable alternative to traditional genetic engineering techniques.
- Open Access
- 19 August 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (34) , 38696-38702
Biological Evaluation of Cleavable Linkers in Exatecan-Based Antibody–Drug Conjugates: A Comparative Study of DXd and Exo-Linker Platforms
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapies that combine the specificity of monoclonal antibodies with the cytotoxicity of potent drug payloads. This study presents the development and evaluation of a novel linker platform designed to enhance ADC stability and pharmacokinetics by addressing the limitations associated with traditional cleavable linkers. Using trastuzumab conjugated with a payload linker consisting of this platform and exo-EVC-Exatecan (APL-1082), we examined key parameters, including in vivo efficacy and pharmacokinetic profiles in rat models, to directly compare it with the clinically validated trastuzumab-deruxtecan (T-DXd, Enhertu). The resulting ADC demonstrated superior stability and maintained drug-to-antibody ratios (DAR) with reduced aggregation and hydrophobicity compared to T-DXd, suggesting an improved pharmacokinetic profile. Additionally, combining APL-1082 with AJICAP site-specific conjugation technology enabled the production of high-DAR ADCs, achieving a DAR of 10 with promising homogeneity and physicochemical properties. Collectively, these findings underscore the potential of this novel linker as a versatile platform for next-generation ADCs, offering enhanced stability, efficacy, and expanded therapeutic possibilities.
- 19 August 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (34) , 38696-38702
Open AccessBiological Evaluation of Cleavable Linkers in Exatecan-Based Antibody–Drug Conjugates: A Comparative Study of DXd and Exo-Linker Platforms
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapies that combine the specificity of monoclonal antibodies with the cytotoxicity of potent drug payloads. This study presents the development and evaluation of a novel linker platform designed to enhance ADC stability and pharmacokinetics by addressing the limitations associated with traditional cleavable linkers. Using trastuzumab conjugated with a payload linker consisting of this platform and exo-EVC-Exatecan (APL-1082), we examined key parameters, including in vivo efficacy and pharmacokinetic profiles in rat models, to directly compare it with the clinically validated trastuzumab-deruxtecan (T-DXd, Enhertu). The resulting ADC demonstrated superior stability and maintained drug-to-antibody ratios (DAR) with reduced aggregation and hydrophobicity compared to T-DXd, suggesting an improved pharmacokinetic profile. Additionally, combining APL-1082 with AJICAP site-specific conjugation technology enabled the production of high-DAR ADCs, achieving a DAR of 10 with promising homogeneity and physicochemical properties. Collectively, these findings underscore the potential of this novel linker as a versatile platform for next-generation ADCs, offering enhanced stability, efficacy, and expanded therapeutic possibilities.
- 30 May 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (7) , 1334-1339
Homogeneous Dual-Payload Antibody-Drug Conjugates Produced by Combined Distinct Conjugation Strategies
Antibody-drug conjugates (ADCs) represent a promising class of targeted cancer therapies, combining monoclonal antibody specificity with cytotoxic drug potency. Despite significant ADC technology advancements, challenges such as limited efficacy, often attributed to tumor heterogeneity and resistance development, remain present. In this study, we developed homogeneous dual-payload ADCs by combining site-selective conjugation methods: second-generation AJICAP technology for lysine modification and conventional interchain-break conjugation. Using trastuzumab as a model antibody, we successfully synthesized a drug-to-antibody ratio (DAR) of 10 (2 + 8) dual-payload ADC with monomethyl auristatin E and deruxtecan, displaying low aggregation and stable physicochemical properties. The dual-payload ADC exhibited superior in vitro cytotoxicity against HER2-positive SKBR-3 cells, compared to T-DXd, and demonstrated enhanced tumor suppression in vivo in a NCI-N87 xenograft model. These results highlight the potential of multipayload ADCs in enhancing therapeutic efficacy while maintaining stability, thereby providing a new strategy to overcome traditional ADC-related limitations.
- 30 May 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (7) , 1334-1339
Homogeneous Dual-Payload Antibody-Drug Conjugates Produced by Combined Distinct Conjugation Strategies
Antibody-drug conjugates (ADCs) represent a promising class of targeted cancer therapies, combining monoclonal antibody specificity with cytotoxic drug potency. Despite significant ADC technology advancements, challenges such as limited efficacy, often attributed to tumor heterogeneity and resistance development, remain present. In this study, we developed homogeneous dual-payload ADCs by combining site-selective conjugation methods: second-generation AJICAP technology for lysine modification and conventional interchain-break conjugation. Using trastuzumab as a model antibody, we successfully synthesized a drug-to-antibody ratio (DAR) of 10 (2 + 8) dual-payload ADC with monomethyl auristatin E and deruxtecan, displaying low aggregation and stable physicochemical properties. The dual-payload ADC exhibited superior in vitro cytotoxicity against HER2-positive SKBR-3 cells, compared to T-DXd, and demonstrated enhanced tumor suppression in vivo in a NCI-N87 xenograft model. These results highlight the potential of multipayload ADCs in enhancing therapeutic efficacy while maintaining stability, thereby providing a new strategy to overcome traditional ADC-related limitations.
- 30 December 2024
- Published by Sunvalley Communication in ADC Review / Journal of Antibody-drug Conjugates
Exo-Linker: Positional Reconfiguration Driving Significant Advances in ADC Stability and Efficacy
Antibody-drug conjugates (ADCs) have transformed targeted cancer therapy by combining the specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. However, payload instability, hydrophobicity, and premature cleavage limit their efficacy and safety. This study presents Exo-Linker technology as a novel solution to these issues. By repositioning cleavable peptide linkers like Glu-Val-Cit and Glu-Glu-Val-Cit at the exo-position of the p-aminobenzyl carbamate moiety, Exo-Linkers improve stability, hydrophilicity, and resistance to enzymatic degradation. Key findings highlight the superior pharmacokinetics, tumor-suppressive efficacy, and enzymatic stability of Exo-Linker ADCs in preclinical models, significantly outperforming traditional Val-Cit-based linkers. Integration with the second-generation AJICAP platform broadens therapeutic windows, ensures precise drug-to-antibody ratio control, and minimizes aggregation. Exo-Linkers establish a new standard for ADC development, overcoming critical limitations of traditional linkers while enabling safer and more effective cancer treatments. This innovative approach redefines the therapeutic landscape, enhances patient outcomes, and broadens the scope of ADC applications.
- 30 December 2024
- Published by Sunvalley Communication in ADC Review / Journal of Antibody-drug Conjugates
Exo-Linker: Positional Reconfiguration Driving Significant Advances in ADC Stability and Efficacy
Antibody-drug conjugates (ADCs) have transformed targeted cancer therapy by combining the specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. However, payload instability, hydrophobicity, and premature cleavage limit their efficacy and safety. This study presents Exo-Linker technology as a novel solution to these issues. By repositioning cleavable peptide linkers like Glu-Val-Cit and Glu-Glu-Val-Cit at the exo-position of the p-aminobenzyl carbamate moiety, Exo-Linkers improve stability, hydrophilicity, and resistance to enzymatic degradation. Key findings highlight the superior pharmacokinetics, tumor-suppressive efficacy, and enzymatic stability of Exo-Linker ADCs in preclinical models, significantly outperforming traditional Val-Cit-based linkers. Integration with the second-generation AJICAP platform broadens therapeutic windows, ensures precise drug-to-antibody ratio control, and minimizes aggregation. Exo-Linkers establish a new standard for ADC development, overcoming critical limitations of traditional linkers while enabling safer and more effective cancer treatments. This innovative approach redefines the therapeutic landscape, enhances patient outcomes, and broadens the scope of ADC applications.
- Open Access
- 4 December 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Exo-Linker: Positional Reconfiguration Driving Significant Advances in ADC Stability and Efficacy
Antibody-drug conjugates (ADCs) have transformed targeted cancer therapy by combining the specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. However, payload instability, hydrophobicity, and premature cleavage limit their efficacy and safety. This study presents Exo-Linker technology as a novel solution to these issues. By repositioning cleavable peptide linkers like Glu-Val-Cit and Glu-Glu-Val-Cit at the exo-position of the p-aminobenzyl carbamate moiety, Exo-Linkers improve stability, hydrophilicity, and resistance to enzymatic degradation. Key findings highlight the superior pharmacokinetics, tumor-suppressive efficacy, and enzymatic stability of Exo-Linker ADCs in preclinical models, significantly outperforming traditional Val-Cit-based linkers. Integration with the second-generation AJICAP platform broadens therapeutic windows, ensures precise drug-to-antibody ratio control, and minimizes aggregation. Exo-Linkers establish a new standard for ADC development, overcoming critical limitations of traditional linkers while enabling safer and more effective cancer treatments. This innovative approach redefines the therapeutic landscape, enhances patient outcomes, and broadens the scope of ADC applications.
- 4 December 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessExo-Linker: Positional Reconfiguration Driving Significant Advances in ADC Stability and Efficacy
Antibody-drug conjugates (ADCs) have transformed targeted cancer therapy by combining the specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. However, payload instability, hydrophobicity, and premature cleavage limit their efficacy and safety. This study presents Exo-Linker technology as a novel solution to these issues. By repositioning cleavable peptide linkers like Glu-Val-Cit and Glu-Glu-Val-Cit at the exo-position of the p-aminobenzyl carbamate moiety, Exo-Linkers improve stability, hydrophilicity, and resistance to enzymatic degradation. Key findings highlight the superior pharmacokinetics, tumor-suppressive efficacy, and enzymatic stability of Exo-Linker ADCs in preclinical models, significantly outperforming traditional Val-Cit-based linkers. Integration with the second-generation AJICAP platform broadens therapeutic windows, ensures precise drug-to-antibody ratio control, and minimizes aggregation. Exo-Linkers establish a new standard for ADC development, overcoming critical limitations of traditional linkers while enabling safer and more effective cancer treatments. This innovative approach redefines the therapeutic landscape, enhances patient outcomes, and broadens the scope of ADC applications.
- Open Access
- 2 December 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Enhanced Chemical Method for Bispecific Antibody Production: Leveraging Site-Specific Conjugation and Stable Crosslinker Technology
Bispecific antibodies (BisAbs) represent a major breakthrough in biotherapeutics by combining the functionalities of two different antibodies to unlock their potential for a wide range of applications. Conventional BisAb production has relied on labor-intensive and complex genetic-engineering methods. This chapter introduces a cutting-edge protocol that circumvents the need for genetic modifications by using chemical conjugation strategies. We present a streamlined, fully chemical methodology for generating BisAbs that leverages the precision of the AJICAP second-generation technology for accurate site-specific conjugation. In addition, this chapter explores the application of haloketone chemistry as an improved and more effective replacement for traditional maleimide-based crosslinking techniques for the fusion of two antibody-related proteins. The analytical performance and results of the newly developed BisAb were thoroughly investigated, highlighting its high efficiency and effectiveness. This innovative approach represents a significant step forward in the production of BisAbs and offers a simpler, more accessible, and potentially scalable alternative to traditional genetic-engineering techniques.
- 2 December 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessEnhanced Chemical Method for Bispecific Antibody Production: Leveraging Site-Specific Conjugation and Stable Crosslinker Technology
Bispecific antibodies (BisAbs) represent a major breakthrough in biotherapeutics by combining the functionalities of two different antibodies to unlock their potential for a wide range of applications. Conventional BisAb production has relied on labor-intensive and complex genetic-engineering methods. This chapter introduces a cutting-edge protocol that circumvents the need for genetic modifications by using chemical conjugation strategies. We present a streamlined, fully chemical methodology for generating BisAbs that leverages the precision of the AJICAP second-generation technology for accurate site-specific conjugation. In addition, this chapter explores the application of haloketone chemistry as an improved and more effective replacement for traditional maleimide-based crosslinking techniques for the fusion of two antibody-related proteins. The analytical performance and results of the newly developed BisAb were thoroughly investigated, highlighting its high efficiency and effectiveness. This innovative approach represents a significant step forward in the production of BisAbs and offers a simpler, more accessible, and potentially scalable alternative to traditional genetic-engineering techniques.
- Open Access
- 12 March 2024
- Published by American Chemical Society (ACS) in ChemRxiv
AJICAP-M: Traceless Affinity Peptide Mediated Conjugation Technology for Site-Specific Antibody-Drug Conjugate Synthesis
A traceless site-selective conjugation method, “AJICAP-M,” was developed for native antibodies at specific sites using Fc-affinity peptides, focusing on Lys248 or Lys288. It produces antibody-drug conjugates (ADCs) with consistent drug-to-antibody ratios, enhanced stability, and simplified manufacturing. Comparative in vivo assessment demonstrated AJICAP-M's superior stability over traditional ADCs. This technology has been successfully applied to continuous-flow manufacturing, marking the first achievement in site-specific ADC production. This manuscript outlines AJICAP-M's methodology and its effectiveness in ADC production.
- 12 March 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAJICAP-M: Traceless Affinity Peptide Mediated Conjugation Technology for Site-Specific Antibody-Drug Conjugate Synthesis
A traceless site-selective conjugation method, “AJICAP-M,” was developed for native antibodies at specific sites using Fc-affinity peptides, focusing on Lys248 or Lys288. It produces antibody-drug conjugates (ADCs) with consistent drug-to-antibody ratios, enhanced stability, and simplified manufacturing. Comparative in vivo assessment demonstrated AJICAP-M's superior stability over traditional ADCs. This technology has been successfully applied to continuous-flow manufacturing, marking the first achievement in site-specific ADC production. This manuscript outlines AJICAP-M's methodology and its effectiveness in ADC production.
- 21 November 2023
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 14 (12) , 1767-1773
Bispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second-Generation
Bispecific antibodies (BisAbs) are biotherapeutics that amalgamate the specificities of two distinct antibodies into one molecule, however, their engineering requires genetic modification and remains time-consuming. Therefore, we used AJICAP second-generation technology, which drives the production of site-specific conjugation without genetic modification requirements, to generate BisAbs. Using haloketone chemistry as an alternative to maleimide chemistry, we successfully produced site-specific antibody conjugates. Pharmacokinetic studies revealed that the haloketone-based antibody conjugate was stable in the rat plasma. The resultant BisAbs were rigorously evaluated, and surface plasmon resonance measurements and flow cytometry analyses confirmed that the antigen binding remained intact. Additionally, the affinity for the neonatal Fc receptor (FcRn) was retained after conjugation. Further cytotoxicity evaluation emphasized the pronounced activity of the generated BisAbs. This novel approach introduces a fully chemical, site-specific strategy capable of producing BisAbs, heralding a new era in the field of biotherapeutics.
- 21 November 2023
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 14 (12) , 1767-1773
Bispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second-Generation
Bispecific antibodies (BisAbs) are biotherapeutics that amalgamate the specificities of two distinct antibodies into one molecule, however, their engineering requires genetic modification and remains time-consuming. Therefore, we used AJICAP second-generation technology, which drives the production of site-specific conjugation without genetic modification requirements, to generate BisAbs. Using haloketone chemistry as an alternative to maleimide chemistry, we successfully produced site-specific antibody conjugates. Pharmacokinetic studies revealed that the haloketone-based antibody conjugate was stable in the rat plasma. The resultant BisAbs were rigorously evaluated, and surface plasmon resonance measurements and flow cytometry analyses confirmed that the antigen binding remained intact. Additionally, the affinity for the neonatal Fc receptor (FcRn) was retained after conjugation. Further cytotoxicity evaluation emphasized the pronounced activity of the generated BisAbs. This novel approach introduces a fully chemical, site-specific strategy capable of producing BisAbs, heralding a new era in the field of biotherapeutics.
- Open Access
- 25 September 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Exo-Cleavable Linkers: A Paradigm Shift for Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates
Customized drug delivery systems have become paramount in the rapidly evolving field of precision medicine, and at the forefront of advances in this regard, antibody-drug conjugates (ADCs) present a symbiotic fusion of cytotoxic payloads and monoclonal antibodies (mAbs) facilitated by intricate chemical linkers. The search for ideal linkers that can dexterously provide the dual functionalities of enhancing circulatory stability and facilitating the effective release of the tumor payload is a present and formidable challenge. The valine-citrulline (Val-Cit) linker, which is used in a wide range of ADCs, despite its approval by the Food and Drug Administration, is associated with several inherent drawbacks, including hydrophobicity-induced aggregation, limited payload capacity, and premature payload release. This study presents a paradigm shift from the conventional linear linker archetype by introducing an exo-linker avant-garde approach that repositions the cleavable peptide linker at the exo-position of the PAB moiety. This molecular refinement not only offered the possibility to overcome the intrinsic drawbacks of the Val-Cit platform, but also significantly improved ADC stability, therapeutic efficacy, and pharmacokinetics. In vitro and in vivo biological evaluations, confirmed that ADCs designed using the exo-linker blueprint significantly attenuated premature payload release, while increasing the drug-to-antibody ratio, even with hydrophobic payloads, and this without inducing pronounced aggregation. Therefore, the fabricated exo-linker represents a significant improvement with respect to traditional Val-Cit ADCs. Moreover, under the influence of enzymes, such as carboxylesterases and human neutrophil elastase, the payload remained stably conjugated to the ADC, underscoring a favorable safety profile and highlighting potential for clinical translatability. Thus, our findings also demonstrate the potential of the novel exo-linker paradigm as well as the profound implications of nuanced molecular modifications for reshaping ADC design and functionality.
- 25 September 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessExo-Cleavable Linkers: A Paradigm Shift for Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates
Customized drug delivery systems have become paramount in the rapidly evolving field of precision medicine, and at the forefront of advances in this regard, antibody-drug conjugates (ADCs) present a symbiotic fusion of cytotoxic payloads and monoclonal antibodies (mAbs) facilitated by intricate chemical linkers. The search for ideal linkers that can dexterously provide the dual functionalities of enhancing circulatory stability and facilitating the effective release of the tumor payload is a present and formidable challenge. The valine-citrulline (Val-Cit) linker, which is used in a wide range of ADCs, despite its approval by the Food and Drug Administration, is associated with several inherent drawbacks, including hydrophobicity-induced aggregation, limited payload capacity, and premature payload release. This study presents a paradigm shift from the conventional linear linker archetype by introducing an exo-linker avant-garde approach that repositions the cleavable peptide linker at the exo-position of the PAB moiety. This molecular refinement not only offered the possibility to overcome the intrinsic drawbacks of the Val-Cit platform, but also significantly improved ADC stability, therapeutic efficacy, and pharmacokinetics. In vitro and in vivo biological evaluations, confirmed that ADCs designed using the exo-linker blueprint significantly attenuated premature payload release, while increasing the drug-to-antibody ratio, even with hydrophobic payloads, and this without inducing pronounced aggregation. Therefore, the fabricated exo-linker represents a significant improvement with respect to traditional Val-Cit ADCs. Moreover, under the influence of enzymes, such as carboxylesterases and human neutrophil elastase, the payload remained stably conjugated to the ADC, underscoring a favorable safety profile and highlighting potential for clinical translatability. Thus, our findings also demonstrate the potential of the novel exo-linker paradigm as well as the profound implications of nuanced molecular modifications for reshaping ADC design and functionality.
- Open Access
- 25 August 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Bispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second Generation
Bispecific antibodies are biotherapeutics that amalgamate the specificities of two distinct antibodies into one molecule. Bispecific antibodies can be utilized in a broad range of diagnostic and therapeutic applications; however, their engineering requires genetic modification and remains time-consuming. Therefore, in this study, we used AJICAP second-generation technology, which drives the production of site-specific antibody-drug conjugates in a practical and robust manner, without genetic modification requirements, to generate bispecific antibodies. Using haloketone chemistry as an alternative to maleimide chemistry, which carries reaction risks, we successfully produced site-specific antibody conjugates. Pharmacokinetic studies revealed that the haloketone-based antibody conjugate was stable in the rat plasma. The resultant bispecific antibodies were rigorously evaluated, and surface plasmon resonance measurements and flow cytometry analyses confirmed that antigen binding remained intact. Additionally, the affinity for the neonatal Fc receptor (FcRn) was retained after conjugation. Further cytotoxicity evaluation emphasized the pronounced activity of the generated bi-specific antibodies. These preliminary findings highlight the potential of AJICAP second-generation technology in BisAb production. This novel approach introduces a fully chemical, site-specific strategy capable of producing bispecific antibodies, heralding a new era in the field of biotherapeutics.
- 25 August 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessBispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second Generation
Bispecific antibodies are biotherapeutics that amalgamate the specificities of two distinct antibodies into one molecule. Bispecific antibodies can be utilized in a broad range of diagnostic and therapeutic applications; however, their engineering requires genetic modification and remains time-consuming. Therefore, in this study, we used AJICAP second-generation technology, which drives the production of site-specific antibody-drug conjugates in a practical and robust manner, without genetic modification requirements, to generate bispecific antibodies. Using haloketone chemistry as an alternative to maleimide chemistry, which carries reaction risks, we successfully produced site-specific antibody conjugates. Pharmacokinetic studies revealed that the haloketone-based antibody conjugate was stable in the rat plasma. The resultant bispecific antibodies were rigorously evaluated, and surface plasmon resonance measurements and flow cytometry analyses confirmed that antigen binding remained intact. Additionally, the affinity for the neonatal Fc receptor (FcRn) was retained after conjugation. Further cytotoxicity evaluation emphasized the pronounced activity of the generated bi-specific antibodies. These preliminary findings highlight the potential of AJICAP second-generation technology in BisAb production. This novel approach introduces a fully chemical, site-specific strategy capable of producing bispecific antibodies, heralding a new era in the field of biotherapeutics.